相似文献
1
Apremilast as a potential treatment option for COVID-19: No symptoms of infection in a psoriatic patient.
Dermatol Ther. 2020 Jul;33(4):e13668. doi: 10.1111/dth.13668. Epub 2020 Jun 24.
2
COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e376-e378. doi: 10.1111/jdv.16625. Epub 2020 Jun 4.
3
Opportunistic virus infections in psoriasis patients: The safer alternative of apremilast in the COVID-19 era.
Dermatol Ther. 2020 Jul;33(4):e13618. doi: 10.1111/dth.13618. Epub 2020 Jun 4.
4
Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice.
J Cutan Med Surg. 2020 Jul/Aug;24(4):418-419. doi: 10.1177/1203475420928382. Epub 2020 May 12.
5
Psoriasis and psoriatic arthritis: How to manage immunosuppressants in COVID-19 days.
Dermatol Ther. 2020 Jul;33(4):e13415. doi: 10.1111/dth.13415. Epub 2020 May 2.
6
Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab.
Dermatol Ther. 2020 Jul;33(4):e13708. doi: 10.1111/dth.13708. Epub 2020 Jun 26.
7
Reply to: "COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution".
J Am Acad Dermatol. 2020 Jun;82(6):e215. doi: 10.1016/j.jaad.2020.03.103. Epub 2020 Apr 10.
8
COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution.
J Am Acad Dermatol. 2020 Jun;82(6):e213. doi: 10.1016/j.jaad.2020.03.079. Epub 2020 Apr 1.
9
COVID-19 era: A chance to learn something new about monitoring psoriatic patients in biological therapy.
Dermatol Ther. 2020 Jul;33(4):e13805. doi: 10.1111/dth.13805. Epub 2020 Jul 13.
10
Use of Apremilast in Patients With Psoriatic Arthritis During the COVID-19 Pandemic: Comment on the Article by Mikuls et al.
Arthritis Rheumatol. 2021 Mar;73(3):547-548. doi: 10.1002/art.41575. Epub 2021 Jan 29.
引用本文的文献
1
Dermatology Publications on COVID-19 during the First Pandemic Year: Creativity or Opportunism?
Life (Basel). 2023 Apr 5;13(4):953. doi: 10.3390/life13040953.
2
Apremilast in Psoriasis Patients With Serious Comorbidities: a Case Series and Systematic Review of Literature.
Dermatol Pract Concept. 2022 Oct 1;12(4):e2022179. doi: 10.5826/dpc.1204a179. eCollection 2022 Nov.
3
Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.
Front Immunol. 2022 Oct 21;13:1046352. doi: 10.3389/fimmu.2022.1046352. eCollection 2022.
4
Apremilast in Paediatric Dermatoses - A Comprehensive Review.
Indian J Dermatol. 2022 Mar-Apr;67(2):206. doi: 10.4103/ijd.ijd_482_21.
5
COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis.
Rheumatol Ther. 2022 Aug;9(4):993-1016. doi: 10.1007/s40744-022-00462-9. Epub 2022 May 22.
6
Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities.
J Clin Med. 2022 Apr 26;11(9):2422. doi: 10.3390/jcm11092422.
7
Apremilast Improves Endothelial Glycocalyx Integrity, Vascular and Left Ventricular Myocardial Function in Psoriasis.
Pharmaceuticals (Basel). 2022 Jan 30;15(2):172. doi: 10.3390/ph15020172.
8
Management of Psoriasis During the Coronavirus Disease 2019 Pandemic.
J Clin Aesthet Dermatol. 2021 Sep;14(9):41-44.
9
Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study.
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e94-e95. doi: 10.1111/jdv.17749. Epub 2021 Oct 28.
10
Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19.
Comput Biol Med. 2020 Nov;126:104051. doi: 10.1016/j.compbiomed.2020.104051. Epub 2020 Oct 10.
本文引用的文献
1
COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e376-e378. doi: 10.1111/jdv.16625. Epub 2020 Jun 4.
2
Improvement of SARS-CoV-2 symptoms following Guselkumab injection in a psoriatic patient.
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e363-e364. doi: 10.1111/jdv.16590. Epub 2020 Jun 4.
3
Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs.
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e360-e361. doi: 10.1111/jdv.16587. Epub 2020 Jun 8.
4
SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor.
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e357-e358. doi: 10.1111/jdv.16571. Epub 2020 Jun 8.
5
Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic.
Am J Clin Dermatol. 2020 Jun;21(3):307-311. doi: 10.1007/s40257-020-00514-2.
6
Should biologics for psoriasis be interrupted in the era of COVID-19?
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
7
COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action.
Dermatol Ther. 2020 Jul;33(4):e13298. doi: 10.1111/dth.13298. Epub 2020 Mar 22.
Zotero 插件